[go: up one dir, main page]

DK0454783T3 - Sted-specifik in vivo aktivering af terapeutiske lægemidler - Google Patents

Sted-specifik in vivo aktivering af terapeutiske lægemidler

Info

Publication number
DK0454783T3
DK0454783T3 DK90902934.0T DK90902934T DK0454783T3 DK 0454783 T3 DK0454783 T3 DK 0454783T3 DK 90902934 T DK90902934 T DK 90902934T DK 0454783 T3 DK0454783 T3 DK 0454783T3
Authority
DK
Denmark
Prior art keywords
activator
prodrug
target tissue
site
targeting moiety
Prior art date
Application number
DK90902934.0T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Pomato
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Carl-Wilhelm Vogel
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0454783(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0454783T3 publication Critical patent/DK0454783T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK90902934.0T 1989-01-23 1990-01-23 Sted-specifik in vivo aktivering af terapeutiske lægemidler DK0454783T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23

Publications (1)

Publication Number Publication Date
DK0454783T3 true DK0454783T3 (da) 1995-10-16

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90902934.0T DK0454783T3 (da) 1989-01-23 1990-01-23 Sted-specifik in vivo aktivering af terapeutiske lægemidler

Country Status (12)

Country Link
EP (1) EP0454783B1 (fr)
JP (1) JP3273608B2 (fr)
KR (1) KR0185967B1 (fr)
AT (1) ATE123414T1 (fr)
AU (1) AU648015B2 (fr)
CA (1) CA2025899A1 (fr)
DE (1) DE69019959T2 (fr)
DK (1) DK0454783T3 (fr)
ES (1) ES2075893T3 (fr)
FI (1) FI97692C (fr)
NO (1) NO912864L (fr)
WO (1) WO1990007929A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DE69034042T2 (de) * 1989-08-02 2003-07-17 Mitra Medical Technology Ab, Lund System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE68928946T2 (de) * 1989-12-11 1999-10-21 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1994001137A1 (fr) * 1992-07-06 1994-01-20 Hybritech Incorporated Procede d'aministration d'agents cytotoxiques et constituants de ceux-ci
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
BR9510490B1 (pt) * 1994-12-23 2010-10-05 composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
CA2227040A1 (fr) 1995-08-16 1997-03-06 Zeneca Limited Composes chimiques
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych
EP3970752A1 (fr) * 2020-09-17 2022-03-23 Merck Patent GmbH Molécules ayant une étiquette de solubilité et procédés associés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
AU618209B2 (en) * 1987-07-02 1991-12-12 Akzo N.V. Antigen recognized by mca 16-88
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
DE69019959T2 (de) 1995-10-05
NO912864L (no) 1991-09-19
JPH04503068A (ja) 1992-06-04
AU5039790A (en) 1990-08-13
NO912864D0 (no) 1991-07-22
KR910700072A (ko) 1991-03-13
DE69019959D1 (de) 1995-07-13
FI97692C (fi) 1997-02-10
EP0454783A1 (fr) 1991-11-06
KR0185967B1 (ko) 1999-05-01
EP0454783A4 (en) 1992-01-15
FI913511A0 (fi) 1991-07-22
ATE123414T1 (de) 1995-06-15
ES2075893T3 (es) 1995-10-16
WO1990007929A1 (fr) 1990-07-26
CA2025899A1 (fr) 1990-07-24
AU648015B2 (en) 1994-04-14
FI97692B (fi) 1996-10-31
EP0454783B1 (fr) 1995-06-07
JP3273608B2 (ja) 2002-04-08

Similar Documents

Publication Publication Date Title
DK0454783T3 (da) Sted-specifik in vivo aktivering af terapeutiske lægemidler
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DK302782A (da) Anvendelse af eucalypol til at foroege et praeparats optagelse gennem huden
DE69232263D1 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
EP0681475A4 (fr) Inhibiteur therapeutique de cellules de muscles vasculaires lisses
DE69715049D1 (de) Tranilast enthaltendes externum und verfahren zu dessen herstellung
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
ATE173627T1 (de) Medizinische zusammensetzung
IL146133A0 (en) Preparations for the application of anti-inflammatory agents
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
AU5643299A (en) Humic acid and its use in the treatment of various conditions
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
DK0559145T3 (da) Lægemiddel til truende abort
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
CY1106819T1 (el) Φαρμακα για το ξηρο δερμα
WO2001007029A3 (fr) Guanidines substitutees et utilisation correspondante
FR2700543B1 (fr) Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
KR890007737A (ko) 진토작용을 하는 약제
DK452788D0 (da) Smertestillende praeparat
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу